RESUMO
Background: The most common types of non-Hodgkin lymphoma (NHL) are diffuse large B cell (DLBCL) and follicular (FL). Aim: To analyze the benefit ofRituxi-mab in overall survival (OS) of patients with NHL. Material and Methods: Review of medical record of 230 adult patients with afirst episode of NHL admitted between 2002 and 2011. We included 67 patients with DLBCL and 36 patients with FL. Results: The overall response (OR) was 64% with 39% complete remissions (CR) in DLBCL treated with CHOP-like and 100% with 89% CR with R-CHOP. The median OS with CHOP-like was 21 months versus not attained R-CHOP (p = 0.016). There was a statistically significant difference in median event-free survival (EvFS) in favor of R-CHOP: not attained versus 8.3 months for CHOP-like (log rank (p = 0.002)). In FL, the OR in patients treated with R-CHOP or R-CHOP-like was 85%) with 54% CR. With CHOP-like the OR was 59%> with 18% CR. The OS at 24 and 36 months in patients treated with R-CHOP or R-CHOP-like was 83 and 65%. The figures for patients treated with CHOP-like were 80 and 66%> respectively. The progression free survival (PFS) was 21 months with CHOP-like versus not attained with R-QT (p = 0,043). Conclusions: When Rituximab was added to CHOP, there was a higher CR, EvFS and OS in DLBCL and higher CR and PFS in FL.
Assuntos
Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Linfoma Folicular/tratamento farmacológico , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Anticorpos Monoclonais Murinos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Ciclofosfamida/administração & dosagem , Intervalo Livre de Doença , Doxorrubicina/administração & dosagem , Linfoma Folicular/mortalidade , Linfoma Difuso de Grandes Células B/mortalidade , Estadiamento de Neoplasias , Prednisona/administração & dosagem , Prognóstico , Resultado do Tratamento , Vincristina/administração & dosagemRESUMO
The purpose of this study was to determine the survival and prognostic factors of patients with diffuse large B-cell lymphoma (DLBCL) of the oral cavity and maxillofacial region. Retrospectively, the clinical records of patients with a primary diagnosis of DLBCL of the oral cavity and maxillofacial region treated at the A.C. Camargo Hospital for Cancer, São Paulo, Brazil, between January 1980 and December 2005 were evaluated to determine (A) overall survival (OS) at 2 and 5 years and the individual survival percentage for each possible prognostic factor by means of the actuarial technique (also known as mortality tables), and the Kaplan Meier product limit method (which provided the survival value curves for each possible prognostic factor); (B) prognostic factors subject to univariate evaluation with the log-rank test (also known as Mantel-Cox), and multivariate analysis with Cox's regression model (all the variables together). The data were considered significant at p ≤ 0.05. From 1980 to 2005, 3513 new cases of lymphomas were treated, of which 151 (4.3%) occurred in the oral cavity and maxillofacial region. Of these 151 lesions, 48 were diffuse large B-cell lymphoma, with 64% for OS at 2 years and 45% for OS at 5 years. Of the variables studied as possible prognostic factors, multivariate analysis found the following variables have statistically significant values: age (p = 0.042), clinical stage (p = 0.007) and performance status (p = 0.031). These data suggest that patients have a higher risk of mortality if they are older, at a later clinical stage, and have a higher performance status.
Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Linfoma Difuso de Grandes Células B/mortalidade , Neoplasias Maxilares/mortalidade , Neoplasias Bucais/mortalidade , Distribuição por Idade , Fatores Etários , Brasil , Estudos Transversais , Métodos Epidemiológicos , Linfoma Difuso de Grandes Células B/patologia , Neoplasias Maxilares/patologia , Neoplasias Bucais/patologia , Estadiamento de Neoplasias , Estudos Retrospectivos , Distribuição por Sexo , Fatores Sexuais , Fatores de TempoRESUMO
El Linfoma de Células Grandes B difuso del anciano asociado al Epstein Barr es una nueva entidad incluida provisionalmente en la más reciente clasificación de neoplasias linfoides de la WHO. Usualmente afecta ancianos y tiene pobre sobrevida. El objetivo de este reporte fue evaluar las característica clínicas, endoscópicas y sobrevida de cinco pacientes portadores de esta entidad y compromiso gastrointestinal. Tres casos tuvieron infiltración gástrica y dos casos tuvieron compromiso del ileón y el ciego.
EBV-positive diffuse large B-cell lymphoma (DLBCL) in elderly is a new entity included provisionally in the most recent WHO Classification of lymphoid neoplasms. It usually affects elderly patients and has a poor survival. The goal of this report was to evaluate clinical, endoscopic characteristics and survival of five patients with this entity and gastrointestinal afectation. From five cases, three cases had gastric infiltration, one ileon and one in cecum.
Assuntos
Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infecções por Vírus Epstein-Barr/complicações , Linfoma Difuso de Grandes Células B/diagnóstico , Neoplasias do Ceco/diagnóstico , Neoplasias do Ceco/mortalidade , Neoplasias do Ceco/virologia , Neoplasias do Íleo/diagnóstico , Neoplasias do Íleo/mortalidade , Neoplasias do Íleo/virologia , Linfoma Difuso de Grandes Células B/mortalidade , Linfoma Difuso de Grandes Células B/virologia , Estudos Retrospectivos , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/mortalidade , Neoplasias Gástricas/virologiaAssuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Linfoma Difuso de Grandes Células B/genética , Polimorfismo de Nucleotídeo Único/genética , Receptores de IgG/genética , Anticorpos Monoclonais Murinos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Genótipo , Linfoma Difuso de Grandes Células B/mortalidade , Estadiamento de Neoplasias , Prednisona/administração & dosagem , Análise de Sobrevida , Resultado do Tratamento , Vincristina/administração & dosagemRESUMO
Se presenta el primer caso de linfoma intravascular de célula grande, una variante del linfoma de células B grandes difuso, diagnosticado en el Hospital Militar Central de Bogotá, en una mujer adulta mayor, quien consultó por un síndrome febril prolongado, pérdida de peso, síntomas constitucionales y quien veinte días antes del ingreso perdió fuerza progresiva, hasta la paraplejia. Se iniciaron estudios para descartar enfermedades neoplásicas, infecciosas y autoinmunes, pero falleció el día catorce de su hospitalización. El estudio post-mortem, realizado cinco horas después, mostró una lesión tumoral maligna de célula grande, limitada a los espacios vasculares de múltiples vísceras. Se planteó como diagnóstico una neoplasia de origen linfoide, que se confirmó posteriormente mediante pruebas inmunohistoquímicas...
This is the first case of intravascular large cell lymphoma diagnosed at the Hospital Militar de Bogota, in an adult female who presented with chronic fever, weight loss, constitutional symptoms and progressive motor deterioration for the previous 20 days to the point of paraplegia. A work up was carried out to rule out neoplastic diseases, infections or autoimmune diseases, but she died on the fourteen hospital day. The autopsy, performed 5 hours post mortem, showed an intravascular large cell malignancy, limited to the vascular spaces of multiple organs. The lymphomatous origin was confirmed posteriorly by immunochemical tests...
Apresenta-se o primeiro caso de linfoma intravascular de célula grande, uma variante do linfoma de células B grandes difuso, diagnosticado no Hospital Militar Central de Bogotá, numa mulher adulta maior, quem conferiu por uma síndrome febril prolongado, perda de peso, sintomas constitucionais e quem vinte dias antes do rendimento perdeu força progressiva, até a paraplegia. Iniciaram-se estudos para descartar doenças neoplásicas, infecciosas e auto-imunes, mas faleceu o dia quatorze de sua hospitalização. O estudo post-mortem, realizado cinco horas depois, mostrou uma lesão tumoral maligna de célula grande, limitada aos espaços vasculares de múltiples vísceras. Propôs-se como diagnóstico uma neoplasia de origem linfóide, que se confirmou posteriormente mediante provas inmunohistoquímicas...
Assuntos
Idoso , Linfoma de Células B , Linfoma Difuso de Grandes Células B , Linfoma Difuso de Grandes Células B/mortalidade , Linfoma de Células B/mortalidadeRESUMO
BACKGROUND/AIMS: Diffuse large B-cell lymphoma (DLBCL) in Koreans is frequently accompanied by extranodal (EN) disease at the time of autologous stem cell transplantation (ASCT). We sought to determine whether high EN involvement affected survival following ASCT in Koreans. METHODS: We reviewed 27 patients who had DLBCL with residual disease at ASCT: 13 with residual disease at nodal site(s) only and 14 with nodal and EN disease. RESULTS: Univariate analysis showed that disease status, lactate dehydrogenase (LDH), and performance status at ASCT were predictors of survival following ASCT. The number of EN sites, as categorized by the International Prognostic Index system, had no prognostic significance. When EN involvement at ASCT was classified as negative or positive, the 2-year overall survival for the negative group was 64%, significantly better than the 14% for the positive group (p=0.021), and the event-free survival for the negative group was 62%, significantly better than the 14% for the positive group (p=0.02). CONCLUSIONS: Patients who had DLBCL with residual EN involvement at ASCT showed worse outcomes following ASCT compared to those without EN disease.
Assuntos
Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Estudos de Coortes , Coreia (Geográfico) , Linfoma Difuso de Grandes Células B/mortalidade , Neoplasia Residual , Estudos Retrospectivos , Transplante de Células-Tronco , Taxa de Sobrevida , Resultado do TratamentoRESUMO
El linfoma gastrico primario, entidad relativamente infrecuente, viene aumentando su incidencia como resultado de las mejores técnicas endoscópicas que permiten la toma de suficiente material de biopsia para el diagnóstico histopatológico. El diagnóstico diferencial histológico se hace con el carcinoma gastrico y con el pseudolinfoma gastrico. La clasificación del estadio de la enfermedad es necesaria para planear el tratamiento y valorar el pronóstico. La resección quirúrgica como modalidad terapéutica ha venido siendo reemplazada por esquemas de quimioterapia y radioterapia combinadas con menores ratas de morbimortalidad y mejores tasas de sobrevida.